Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
RPL7P22 is a processed pseudogene in humans, its sequence derived from the functional ribosomal protein L7 gene (RPL7). Unlike its parent gene, RPL7P22 does not encode an active protein and lacks a well-defined biological or molecular function. Processed pseudogenes are generated by reverse transcription and insertion of mRNA back into the genome, and while some pseudogenes are implicated in gene regulation, RPL7P22 is not recognized as a functional pseudogene with disease or therapeutic relevance. In summary, RPL7P22 is not a valid molecular target for therapeutic or diagnostic purposes; it is a processed pseudogene, not a protein nor a functional receptor, enzyme, or other known druggable target class.
None; as a pseudogene, it does not possess a known mechanism of action in pharmacology or biology
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Ribosomal protein L7 pseudogene 22 (RPL7P22).